Anti-FGFR4 mAb

About EvlaBio

EvlaBio is a private, preclinical-stage biotech addressing a critical unmet need in cardiorenal medicine: left ventricular hypertrophy in chronic kidney disease patients. The company's core asset is a highly selective anti-FGFR4 monoclonal antibody designed to block the pathological cardiac signaling driven by elevated FGF23, a hallmark of CKD. Backed by €21 million in seed funding from leading biotech VCs, EvlaBio is advancing its novel therapeutic candidate toward clinical development. The company aims to redefine treatment in a large patient population with very limited current options, targeting a key driver of cardiovascular mortality in CKD.

Therapeutic Areas